A patent gives you the right to stop others from selling, offering for sale of your patented invention. It is your own intellectual property. By holding a patent, you bar another person and the whole world from using your patent. But Patent Infringement occurs in every sector of the economy. Patent Infringement means the allegation by the patent owner that another product in the market is infringing his patent. There are two types of infringement in US direct and indirect infringement. If the infringer uses each element of the patent holders claim it is known as direct infringement. The accused infringer does not use each element of the patent holder’s claim but the product performs the same function as that of patent holder’s then it is known as indirect infringement.
Biopharmaceutical drug developer UCB along with other companies has sued more than 15 drug makers in US including India’s Ranbaxy, Aurobindo, Zydus, Sun Pharma, Glenmark alleging infringement of its epilepsy drug Vimpat (lacosamide). The suit was filed in the US District Court. UCB is planning to stop other companies from entering the market before 2022 when their patent expires. The drug manufactured by UCB is used as an adjunctive therapy in the treatment of partial onset of seizures in people with epilepsy. The patent which was granted on 2004 has US sales of $338 million.
The global market size for the epilepsy drug is estimated to be more than 2 billion with around more than 5 million people suffering from it.
Biopharmaceutical drug developer UCB along with other companies has sued more than 15 drug makers in US including India’s Ranbaxy, Aurobindo, Zydus, Sun Pharma, Glenmark alleging infringement of its epilepsy drug Vimpat (lacosamide). The suit was filed in the US District Court. UCB is planning to stop other companies from entering the market before 2022 when their patent expires. The drug manufactured by UCB is used as an adjunctive therapy in the treatment of partial onset of seizures in people with epilepsy. The patent which was granted on 2004 has US sales of $338 million.
The global market size for the epilepsy drug is estimated to be more than 2 billion with around more than 5 million people suffering from it.
